RT @mattpappas: @NephroGuy @medpedshosp @rabihmgeha @DxRxEdu (To the question of whether bridging is necessary:) I would argue that bridgin…
RT @mattpappas: @NephroGuy @medpedshosp @rabihmgeha @DxRxEdu (To the question of whether bridging is necessary:) I would argue that bridgin…
RT @mattpappas: @NephroGuy @medpedshosp @rabihmgeha @DxRxEdu (To the question of whether bridging is necessary:) I would argue that bridgin…
@NephroGuy @medpedshosp @rabihmgeha @DxRxEdu (To the question of whether bridging is necessary:) I would argue that bridging is very unlikely to be helpful, on balance. For most patients, it’s more likely to harm than to help: https://t.co/fsHIWH3mT2
RT @mattpappas: @KurtPfeifer @medpedshosp @BobbieJeanSwei1 @PeriopSummit @SPAQIedu I have something for that pesky “high-risk” population f…
RT @mattpappas: @KurtPfeifer @medpedshosp @BobbieJeanSwei1 @PeriopSummit @SPAQIedu I have something for that pesky “high-risk” population f…
@KurtPfeifer @medpedshosp @BobbieJeanSwei1 @PeriopSummit @SPAQIedu I have something for that pesky “high-risk” population for which we have so little outcomes data: https://t.co/goiAE0S1jP
RT @JournalGIM: No single trial can capture the full spectrum of benefit and harm. Bridging is harmful for unselected patients, but can be…
@CCF_IMCHIEFS @CleClinicMD
RT @JournalGIM: No single trial can capture the full spectrum of benefit and harm. Bridging is harmful for unselected patients, but can be…
No single trial can capture the full spectrum of benefit and harm. Bridging is harmful for unselected patients, but can be both helpful and cost-effective for patients carefully selected by both bleeding and stroke risk. @mattpappas @ClevelandClinic https:
RT @mattpappas: New paper out today in @JournalGIM (https://t.co/khFXKUdYwB), in which my coauthors and I estimate the utility and cost-eff…
RT @mattpappas: New paper out today in @JournalGIM (https://t.co/khFXKUdYwB), in which my coauthors and I estimate the utility and cost-eff…
RT @mattpappas: New paper out today in @JournalGIM (https://t.co/khFXKUdYwB), in which my coauthors and I estimate the utility and cost-eff…
RT @mattpappas: New paper out today in @JournalGIM (https://t.co/khFXKUdYwB), in which my coauthors and I estimate the utility and cost-eff…
RT @mattpappas: New paper out today in @JournalGIM (https://t.co/khFXKUdYwB), in which my coauthors and I estimate the utility and cost-eff…
Worth a read. Lots of mystery surrounding the need for anticoagulation bridging with huge practice variations. A blanket approach likely to do more harm than good.
RT @mattpappas: New paper out today in @JournalGIM (https://t.co/khFXKUdYwB), in which my coauthors and I estimate the utility and cost-eff…
RT @mattpappas: New paper out today in @JournalGIM (https://t.co/khFXKUdYwB), in which my coauthors and I estimate the utility and cost-eff…
RT @mattpappas: New paper out today in @JournalGIM (https://t.co/khFXKUdYwB), in which my coauthors and I estimate the utility and cost-eff…
Great nuanced discussion on how to think about bridging your anticoagulated patients here...
RT @mattpappas: New paper out today in @JournalGIM (https://t.co/khFXKUdYwB), in which my coauthors and I estimate the utility and cost-eff…
New paper out today in @JournalGIM (https://t.co/khFXKUdYwB), in which my coauthors and I estimate the utility and cost-effectiveness of bridging anticoagulation. Clinical takeaways: (1/7)
@mattpappas - I was waiting to see this in press! @thecurbsiders @COREIMpodcast - he is an intellectually brilliant guy; Would be a terrific contibutor for a podcast.
Cost-Effectiveness of Bridging Anticoagulation Among Patients with Nonvalvular Atrial Fibrillation https://t.co/gSUcUJKNFD